Manufacturing

Chris Spivey is the editorial director of 

Articles

Chris Spivey, editorial director for Pharmaceutical Technology, discusses messenger RNA (mRNA) advances with Guillaume Roelandts, Head of Products and Marketing, Quantoom Biosciences, at the 11th International mRNA Health Conference in Berlin, Germany.

Tackling Production Challenges through Greater Access to mRNA Technologies

Feliza Mirasol is the science editor for 

Novartis and Legend Biotech seek to advance certain CAR-T cell therapy candidates targeting Delta-like ligand protein 3.

Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies

CDMOs are actively exploring and leveraging both new and existing technologies to streamline the cell-line development process at every step.

It’s Time for CDMOs to Embrace the CRISPR Advantage

Matthew Hewitt is vice-president, technical officer, Cell & Gene Therapy & Biologics at Charles River Laboratories.

Larry Bellot, PhD, is scientific advisor, Cell and Gene Therapy, at Charles River Laboratories.

Chad Andersen is associate director, Manufacturing Sciences & Technology, at Charles River Laboratories.

A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.

Best Practice Tech Transfer Methods for CGTs

Chris Spivey, editorial director, hosts a wide ranging discussion on the COVID-19 pandemic response, future government communications, and healthcare funding for mRNA with experts Dr. Kate Broderick, Chief Innovation Officer, Maravai LifeSciences and Dr. Tom Madden, President & CEO at Acuitas Therapeutics. Highlights include supply chain modalities, ensuring a fully trained manufacturing workforce, combining delivery with gene editing innovations, epigenetic approaches to modulate gene expression moving toward the clinic. We conclude with the huge potential for RNA expression of monoclonal antibodies and protein replacement applications.

Exploring mRNA’s Potential

Videos

Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the requirements needed to be successful in global cell therapy as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."

Global Cell Therapy Requirements Need Thorough Understanding (PDA/FDA Joint Regulatory Conference 2023)

Under an expanded agreement, Cellares will provide proof-of-concept manufacturing for a second CAR-T cell therapy from Bristol Myers Squibb.

Cellares Expands Agreement with Bristol Myers Squibb for Second CAR-T Program 

The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond.

eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities 

Humberto Vega, PhD, Executive Director, Bristol Myers Squibb, discusses the journey from clinical to commercial cell therapies as a part of his session, "Successfully Navigating Global Cell Therapy Requirements."

The Challenges of the Journey from Clinical to Commercial Cell Therapies (PDA/FDA Joint Regulatory Conference 2023)

Bassem Gayed, PhD, Senior Technical Director of CAR-T Process Engineering, Manufacturing Science & Technology at Bristol Myers Squibb, discusses the importance of CAR-T as a modality and other highlights from his part of the session, "Process Validation for CAR-T Products: A Continuous Journey."

Manufacturing, Cell Therapies